Vancouver’s AbCellera has launched its first human trial of ABCL635, a menopause-related drug targeting hot flashes. The milestone marks the company’s transition to a clinical-stage biotech firm, CEO Carl Hansen said.
AbCellera is also enrolling patients in a trial for a potential eczema treatment. Known for its partnerships—most notably with Eli Lilly on COVID-19 treatments—AbCellera reported a Q2 loss of US$34.7 million on US$17.1 million in revenue. Despite the loss, the company has US$753 million in liquidity and added nine new partner projects this year, bringing its total to 102.
Want to know more? Check out the source code on The Logic.